Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q4 2017 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$515.00K$515.00Kderived−1.7% vs Q4 2016 Net Income-$1.85M-$1.85MderivedN/M vs Q4 2016 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$1,414,000N/M Operating Cash Flowderived-$1,169,000N/M Free Cash Flowderived-$1,170,000N/M Margins · derivedOperating margin-274.6%+1.6 pt vs Q4 2016
Net margin-358.4%−228.9 pt vs Q4 2016
ended Jul 31, 2017 · filed Oct 26, 2017 · 87 d after period end